---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-038444"
form_type: "8-K"
ticker: "FENC"
cik: "0001211583"
company_name: "FENNEC PHARMACEUTICALS INC."
filed_at: "2024-03-25T23:59:59+00:00"
generated_at: "2026-06-04T08:21:11.856967+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Fennec Pharma FY2023 PEDMARK sales $21.3M, Q4 net loss $2.7M; $43M licensing deal bolsters cash

## Summary
- FY2023 PEDMARK net product sales $21.3M (vs $1.5M in 2022); Q4 net sales $9.7M.
- Net loss for FY2023 $16.0M ($0.60 per share) vs $23.7M ($0.90) in 2022; Q4 net loss $2.7M ($0.10).
- Cash and equivalents $13.2M at Dec 31, 2023; pro forma cash >$55M after receiving ~$43M upfront from Norgine licensing deal.
- Entered exclusive licensing agreement with Norgine for PEDMARQSI in Europe, Australia, NZ; potential up to ~$230M milestones plus tiered royalties.
- FDA issued public reminder that PEDMARK is not substitutable with other sodium thiosulfate products.

## SEC filing metadata
- accession: 0001104659-24-038444
- form_type: 8-K
- ticker: FENC
- cik: 0001211583
- company_name: FENNEC PHARMACEUTICALS INC.
- filed_at: 2024-03-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1211583/000110465924038444/0001104659-24-038444-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1211583/000110465924038444/tm249737d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-038444
- JSON: https://secwatch.observer/filing/0001104659-24-038444.json
- Plain text: https://secwatch.observer/filing/0001104659-24-038444.txt

## Key facts
- Earnings Releases
  FENNEC PHARMACEUTICALS INC. reported financial results for full year and fourth quarter 2023.
  - Period: full year and fourth quarter 2023
  - Result: reported results
  source text: Fennec Pharmaceuticals Inc. issued a news release announcing full year and fourth quarter financial results for the period ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1211583/000110465924038444/0001104659-24-038444-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.